PLANNING GRANT FOR MINORITY INSTITUTION/CANCER CENTER COLLABORATION

Release Date:  March 19, 2001

RFA:  RFA-CA-02-006 (see replacement RFA-CA-03-009)

National Cancer Institute

Letter of Intent Receipt Date:  July 9, 2001
Application Receipt Date:       August 13, 2001

This RFA is a reissue of RFA-CA-01-003, which was published in the NIH Guide 
on April 25, 2000.

PURPOSE

The National Cancer Institute (NCI) invites planning grant applications (i.e., 
P20s) to help researchers and faculty in Minority Serving Institutions (MSIs) 
in collaboration with the researchers and faculty of NCI-designated Cancer 
Centers (or other institutions with highly organized, integrated research 
efforts focused on cancer) plan and implement focused collaborations in cancer 
research, cancer research training and career development or cancer education 
that will lead to the submission of specific grant applications traditionally 
supported by the NCI.  Depending on prior experience, interactions and 
progress in planning, applicants may apply for two-year or three-year P20 
MI/CCP awards.  Applicants requesting three years of support must clearly 
describe a planning stage, a priority setting stage, and an implementation 
stage.  Applicants requesting two years of support who have already identified 
areas of potential collaboration through planning, must document prior 
planning activities and clearly describe a priority-setting stage and an 
implementation stage.  Planning grants must be focused on one or two of the 
above targeted areas that work toward the following objectives:
 
1. Develop a collaborative research project with a minority investigator; 

2. Develop collaborative training and career development programs between MSIs 
and Cancer Centers designed to train minority scientists; and 

3. Develop collaborative education programs designed to motivate minority 
students (e.g., high school and undergraduate) to pursue cancer research 
careers.

The expectation is that these planning grants will become the basis for 
generating specific competitive research grant applications (e.g., R03s, R01s, 
projects on P01s, projects on P50s); training and career development grant 
applications (e.g., T32s, K12s, R25Ts); and or cancer education grant 
applications (e.g., R25Es) funded by the NIH, NCI and other research funding 
organizations (e.g., American Cancer Society). 

OBJECTIVES  

Background: 

Minority-Serving Institutions (MSIs) [e.g., Minority Medical Schools, 
Historically Black Colleges and Universities (HBCUs), Hispanic-Serving 
Institutions (HSIs), Tribal Institutions (e.g., Colleges)] conduct high 
quality programs for educating minorities, and they represent a rich source of 
talent with appropriate cultural sensitivity and perspectives needed in cancer 
research. However, MSIs have had difficulties developing and sustaining 
independent programs in biomedical research, and there is a paucity of 
minority scientists who are pursuing successful biomedical research careers.  
Despite various initiatives by the community and the National Institutes of 
Health (NIH), progress in realizing a significant increase in the number of 
minority scientists who are competitive for NIH research grants has been slow.  
More specifically, there remains a serious shortage of funded minority 
scientists who can conduct independent cancer research, who can focus research 
efforts on the disproportionate incidence, mortality and morbidity rates in 
minority populations and who can bring the cultural perspectives that are 
essential to the successful conduct of many forms of research involving 
minority patients and populations.  
 
The low involvement of MSIs in cancer research and lack of significant 
training of minority scientists in cancer research must be addressed if we are 
to develop a stronger national cancer research effort aimed at understanding 
the disparities of cancer incidence and mortality in minorities compared to 
majority populations. The prospect for identifying and training minority 
students and faculty in areas of cancer research have not been fully explored.  
One untried and potentially powerful approach for addressing these difficult 
issues is to create and sustain collaborations between the scientists and 
faculty of MSIs and Cancer Centers in ways that integrate and take maximum 
advantage of their respective expertise and experience.
 
Three broad areas can be targeted for focused planning, development, and 
implementation:
 
1. Cancer Research: Joint research projects may be in any area of basic, 
clinical, prevention, control, behavioral, or population research. Joint 
cancer research projects might focus, for example, on general areas of 
environmental carcinogenesis, molecular epidemiology, and behavioral issues 
related to cancer prevention, treatment and control.  Successful planning 
efforts and pilot research projects are expected to result in the submission 
of competitive investigator-initiated research grant application (e.g., R03, 
R01, project on a P01, project on a P50).

2. Cancer Research Training and Career Development: Cancer research training 
programs must focus on joint programs organized and conducted by the 
scientists and faculty of both the MSI and Cancer Center that focus on the 
training of minority scientists. The NCI particularly encourages training of 
minority scientists in clinical, behavioral and population research; there is 
a huge deficit of minority scientists engaged in these research areas, areas 
which are highly dependent for their success on the cultural sensitivity of 
the researchers.  These training programs must represent true collaborations 
that function seamlessly across the institutional boundaries of the MSI and 
the Cancer Center.  Successful planning activities and pilot training and 
career development programs should result in the submission of multi-
institutional training grants (e.g., T32, R25T, K12).

3. Cancer Education: Cancer education programs could focus on any effort to 
augment existing or create new curricula in the MSI and/or the Cancer Center 
that would focus on minority students at earlier stages of their educational 
experience (e.g., high school, undergraduate) and that would motivate them to 
pursue careers in cancer research.  A successful planning effort in this area 
is expected to result in the submission of a competitive R25E application and 
later to institutional commitments to make these curricula an inherent 
component of their educational systems.

SPECIAL REQUIREMENTS AND PROVISIONS OF PLANNING GRANTS FOR MINORITY 
INSTITUTION/CANCER CENTER COLLABORATIONS (P20)

There are a number of Special Requirements and Provisions that each Minority 
Institution/Cancer Center Collaboration planning grant application must comply 
with: 

1. Planning grants must be focused on one or two but not three of the 
following targeted areas: 
a) cancer research; b) cancer research training and career development; or c) 
cancer education.

2. When the Principal Investigator from the MSI or Cancer Center is a less 
experienced scientist, there must be a written "Letter of Support" from a 
senior member of the MSI/Cancer Center (e.g., Department Chair, Dean, Cancer 
Center Director) that is fully supportive of this activity to ensure 
appropriate institutional mentoring and provide the maximum chance of success. 

3. Each collaborative planning activity must be submitted as a clear 
partnership between the MSI and Cancer Center.  This must be done by 
submitting two separate planning grant applications, one from the MSI and one 
from the Cancer Center.  The Principal Investigator of the MSI grant 
application must be the Co-Investigator of the Cancer Center grant application 
and vice versa. The overall objectives of the two applications must be the 
same, but the actual activities and budgets of the two applications should 
demonstrate how the MSI and the Cancer Center requests both differ and 
complement each other in achieving their common objectives.  

4. Depending upon prior experience, interactions and progress in planning, the 
two applications must clearly describe a collaborative planning process 
outlining:

   a. Initial Planning Stage (for those applicants requesting three years of 
support) in which the participants must describe appropriate means of 
communicating and identifying areas of potential collaborations. 

   b. Priority-Setting Stage in which specific defined areas of focused 
collaboration and strategies are selected for implementation, and

   c. Implementation Stage of pilot project/programs in which preliminary data 
is acquired for the purpose of submitting a specific competitive grant 
application in one or two of the target areas mentioned above to the NCI or 
other funding agencies.

5. The direct costs of the two applications together cannot exceed $250,000 
per year.  The amount requested should be appropriate to the stage of 
development because the planning and priority-setting stages are not as costly 
as the implementation stage, budget requests would be expected to escalate 
progressively in years 1, 2 and 3 or years 1 and 2.  If there are third party 
subcontract costs, only the direct costs of the subcontract will count against 
this cap.

6. The use of funds to support pilot projects and pilot programs must be for 
totally new activities that do not overlap in purpose or intent with existing 
funded grants (e.g., P30, P50, P01, R01, National Center for Research 
Resources’ Research Infrastructure Grants, National Institute of General 
Medical Sciences’ Minority Biomedical Research Support Grants, other peer-
reviewed funded program).

7. All recipients of P20 MI/CCP awards will be expected to participate in an 
annual meeting sponsored by the Comprehensive Minority Biomedical Branch 
(CMBB) of the NCI.  Travel for this purpose can be included in the grant 
applications from the MSI and the Cancer Center institution.

MECHANISM OF SUPPORT 

This RFA will use the National Institutes of Health (NIH) P20 or planning 
grant mechanism.  The Principal Investigators on behalf of the institutions 
are responsible for the conduct of this planning grant enabling the success of 
the collaboration.

This RFA is a one-time solicitation. If it is determined that there is a 
continuing program need, the NCI will either reissue this RFA for re-
competition or invite recipients of awards under this RFA to submit 
competitive continuation applications for review. 

ALLOWABLE COSTS 

The P20 will provide support for:

1. Administrative costs for managing the planning effort, such as salaries for 
key personnel, travel for key personnel, equipment and supplies to support an 
administrative structure.

2. Developmental costs for:

   a. Initial Planning Stage: for workshops, seminars, retreats and other 
forms of communication to explore potential opportunities in cancer research, 
cancer training and career development or cancer education. 

   b. Priority-setting Stage: for selecting the areas of greatest promise for 
implementation as specific types of pilot projects or programs based on merit 
and potential to result in a successful grant application.

   c. Implementation Stage: for implementing pilot research projects or pilot 
programs in training and career development or education for the explicit 
purpose of obtaining preliminary data for the submission of a specific grant 
application(s).

FUNDS AVAILABLE

NCI anticipates making up to six (three-pair) two-year awards and six (three 
pair) three-year awards, and plan to set aside a total of $4.0 million for the 
first year of funding. The total annual directs cost budgets for the MSI and 
the Cancer Center applications together are expected to range between $50,000 
and $250,000 each year depending upon prior progress in planning and setting 
priorities. The amount requested should be specific to the stage of 
development, for example, planning and priority-setting stages are not as 
costly as the implementation stage. Third party contractual Facilities and 
Administrative costs will not be counted toward the maximum combined direct 
costs of $250,000. Applications exceeding the $250,000 direct cost limit will 
be considered unresponsive to this RFA and will be returned without further 
consideration.  Funding in response to this RFA is dependent upon the receipt 
of a sufficient number of meritorious applications. Although this program is 
provided for in the financial plans of NCI, the award of grants pursuant to 
this RFA is contingent upon the anticipated availability of funds for this 
purpose. Awards are not renewable.  The NCI will make a commitment for funding 
the collaboration for the full term of the award.  The anticipated award date 
is April 1, 2002.  The total project period for applications submitted in 
response to this RFA may not exceed three years.

ELIGIBILITY REQUIREMENTS 

Applications will only be accepted from Minority-Serving Institutions (MSIs) 
[eg., Historically Black Colleges and Universities (HBCUs), Hispanic-Serving 
Institutions (HSIs) and Tribal Institutions (e.g., Colleges)], either in the 
United States or in territories under U.S. jurisdiction, and from institutions 
that are NCI-designated Cancer Centers or from other institutions that can 
demonstrate organized, highly integrated research efforts focused on cancer. 
Minority-Serving Institutions are defined as those in which students of 
minority groups, who are underrepresented in the biomedical sciences (e.g., 
African Americans, Hispanics, Native Americans, Alaskan Natives, Native 
Hawaiians, Pacific Islanders), comprise a significant proportion of the 
enrollments and that have a track record of commitment to the special 
encouragement of minority faculty, students and investigators.  Both MSIs with 
medical schools and MSIs with more focused research and education programs 
(e.g., Masters, and Ph.D. programs) are invited to participate in this 
initiative.  MSIs that offer only baccalaureate degrees, and Tribal 
Institutions (e.g., Colleges) are encouraged to participate in this initiative 
as full collaborators, especially in the development of educational programs 
aimed at motivating students to enter careers in cancer research.  A partial 
list of eligible Minority-Serving Institutions can be found at the following 
website address: http://www.sciencewise.com/.  Other institutions that 
meet the MSI qualifications may not be listed at this website, but they are 
also eligible to apply.  A list of NCI-designated Cancer Centers can be found 
at the following website address: http://www.nci.nih.gov/cancercenters/.

The Principal Investigators must be U.S. citizens, non-citizen alien 
nationals, or permanent residents of the United States.
 
INQUIRIES

Written, telephone, fax and e-mail inquiries concerning this RFA are 
encouraged especially during the planning phase of these applications.  Below 
is a listing of program (i.e., scientific management), grants administration 
(i.e. fiscal management) and review (i.e., management of peer review process) 
staff of the NCI who are available for inquiries:
 
Direct inquiries regarding scientific or programmatic issues to:
 
Sanya A. Springfield, Ph.D.
Chief, CMBB, OCTR, ODDES
National Cancer Institute
6116 Executive Blvd.
Suite 7018A
Bethesda, MD 20892-8347
Telephone: (301) 496-7344
Fax: (301) 402-4551
Email: springfs@mail.nih.gov
 
	Or
 
Brian Kimes, Ph.D.
Director, OCTR, ODDES
National Cancer Institute
6116 Executive Blvd.
Suite 7001
Bethesda, MD 20892-8347
Telephone: (301) 496-8537
Fax: (301) 402-0181
Email: kimesb@mail.nih.gov

Direct inquiries regarding fiscal or budget matters to:

Ms. Barbara Fisher
Grants Management Specialist
National Cancer Institute
6120 Executive Blvd.
EPS/243
Bethesda, MD 20892
Telephone (301) 846-1015
Fax: (301) 846-1198 or 846-5720
Email: bf18m@nih.gov
 
Direct inquiries regarding review matters to:
 
Ms Toby Friedberg
Referral Officer
Division of Extramural Activities
6116 Executive Boulevard, Room 8109, MSC 8239 
Rockville, MD 20852 (express service) 
Bethesda, MD 20892-8239
Telephone (301) 496-3428
Fax: (301) 402-0275
Email: tf12w@nih.gov

PREAPPLICATION TECHNICAL ASSISTANCE WORKSHOP

The NCI strongly encourages all potential applicants to attend a pre-
application Technical Assistance Workshop (TAW) scheduled for May 6-8, 2001.  
Since this is an entirely new concept for the NCI and for the applicant 
population, it will give staff the opportunity to clarify any perceived 
ambiguities in the RFA and to help applicants to present their strongest case 
for developing an application. If one is unable to attend the TAW, the results 
of the workshop can be accessed at the Website: 
http://deainfo.nci.nih.gov/cmbs/index.htm.

In addition, NCI strongly encourages pre-application consultations with 
individual collaborators either as telephone conference calls, 
videoconferences or face to face meetings.  In order to make these 
arrangements contact Dr. Sanya A. Springfield by email at 
springfs@mail.nih.gov or by telephone at (301) 496-7344 or Dr. Brian Kimes by 
email at kimesb@mail.nih.gov or by telephone at (301) 496-8537.

LETTER OF INTENT

Prospective applicants are asked to submit by July 9, 2001, a letter of intent 
that includes a descriptive title of the proposed P20 collaboration, address 
and telephone number of the Co-Investigators, the identities of other key 
personnel and participating institutions, and the number and title of the RFA 
to which the application is being submitted.  Although a letter of intent is 
not required, is not binding, and does not enter into the review of a 
subsequent application, the information that it contains allows NCI staff to 
estimate the potential review workload and plan the review. The letter of 
intent is to be sent to the program staff members listed under INQUIRIES by 
the letter of intent receipt date.

SCHEDULE

Pre-application TAW Meeting Date:  May 6-8 2001 
Letter of Intent Receipt Date:     July 9, 2001
Application Receipt Date:          August 13, 2001
Peer Review:                       November/December, 2001
Review by NCAB:                    February, 2002
Earliest Anticipated Award Date:   April 1, 2002
 
NON-COMPETING CONTINUATION APPLICATION
 
For those applications that are funded, the NCI will provide special 
instructions for submitting the Non-Competing Application each year.

APPLICATION PROCEDURES  

The following procedures apply to both the MSI application and the Cancer 
Center application, which are to be submitted as a collaborative effort:
 
Applications are to be submitted using the Form PHS 398 (rev. 4/98) using the 
SUPPLEMENTAL INSTRUCTIONS provided below and at: 
http://deainfo.nci.nih.gov/cmbs/index.htm on or before August 13, 2001.  A 
Form PHS 398  (rev. 4/98) application kit is available at most institutional 
offices of sponsored research and from the Division of Extramural Outreach and 
Information Resources, National Institutes of Health, 6701 Rockledge Drive, 
MSC 7910, Bethesda, MD 20892-7910, Phone: (301) 435-0714; FAX: (301) 480-0525; 
Email: grantsinfo@nih.gov.  Forms are also available on the following NIH 
website: http://grants.nih.gov/grants/funding/phs398/phs398.html.
 
NOTE:  The RFA label available in the PHS 398 (rev. 4/98) application form 
must be affixed to the bottom of the face page of the application and the 
title "P20 MI/CCP" must be typed on line 2 of the face page of the application 
form and the YES box must be marked.  Type the RFA number on the label.  
Failure to do so could result in delayed processing of the application such 
that it may not reach the review committee in time for the review.

The sample RFA label is available at:  
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been modified to 
allow for this change. Please note this is in pdf format.
 
A cover letter must be attached to the application clearly defining the MSI or 
Cancer Center collaborator; this will allow the NCI to assemble the two 
applications as one package for peer review.  Submit signed, typewritten 
originals of the cover letters, the MSI application and the Cancer Center 
application with their checklists, and three signed photocopies to:
 
Center for Scientific Review 
National Institutes of Health
6701 Rockledge Drive, Room 1040
MSC 7710
Bethesda, MD 20892-7710 or
Bethesda, MD 20817-7710 (for express/courier service)
 
At the time of submission, two additional copies of the cover letter and 
application must be sent to:
 
Ms. Toby Friedberg
Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Blvd., Room 8109
MSC 8329
Bethesda, MD 20892-8329
Rockville, MD 20852 (for express/courier service)
 
As noted above the instructions for the Form PHS 398 do not entirely apply to 
the submission of these P20 MI/CCP grant application.  Accordingly, the NCI 
strongly suggests that you follow the SUPPLEMENTAL INSTRUCTIONS below, which 
have been adapted to accommodate the Form PHS 398, and the special needs of 
this P20 MI/CCP RFA.  These instructions include all of the information that 
will be needed by the peer reviewers of your applications.
 
SUPPLEMENTAL INSTRUCTIONS
 
1. Face Page: Use page AA as instructed in the Form PHS 398.  On line provide 
a title that is representative of your collaboration or partnership.  This 
title should be the same for both the MSI application and the Cancer Center 
institution's application.  For line 2 enter the title "P20 MI/CCP" and the 
number beginning with RFA-CA-02-006.  Remember to affix the RFA label that 
comes with the Form PHS 398 to the bottom of the Face Page.

2. Description, Performance Sites and Key Personnel: Use page 2 of the Form 
PHS 398 and follow the instructions provided in the Form PHS 398.

3. Table of Contents:  Organize the Table of Contents as described below:
 
Content
Page Number

Face Page
Description, Performance Sites and Key Personnel
Table of Contents
Detailed Budget for Initial Budget Period
Budget for Entire Proposed Period of Support
Budgets Pertaining to Consortium/Contractual Arrangements (if more than one 
MSI/Cancer Center is involved)
Biographical Sketch of the Principal Investigator (not to exceed two pages)
Biographical Sketch of the Co-Investigator (not to exceed two pages)
Biographical Sketches of Key Professional Personnel of the MSI or Cancer Center 
(not to exceed two pages for each individual)
List of participating members of the MSI or the Cancer Center
Other Support of Principal Investigator, Co-Investigator and Key Personnel 
Resources 

COLLABORATIVE PLAN:
Introduction to revised application, if applicable (not to exceed three pages)
A. Background 
B. Letter of Support from the MSI/Cancer Center (as necessary for less 
experienced Principal and Co-Principal Investigators)
C. Chronological Estimate of each Stage
D. Initial Planning Stage (as appropriate depending upon prior experience, 
interactions and progress in planning)
E. Priority-setting Stage 
F. Implementation Stage, (as appropriate depending on prior experience, 
interactions and progress in planning)
G. Human Subjects
H. Vertebrate Animals
I. Literature Cited
J. Consortium/Contractual Arrangements
Appendix Material
Checklist
 
4. Detailed Budget for Initial Budget Period as appropriate to the stage of 
development: Use DD (form page 4) of the Form PHS 398 application kit. It is 
expected that requested costs in the first year will be less than costs in the 
second or third years because planning and priority-setting are not as 
expensive as the implementation of a project or a program. 

5. Budget for Entire Proposed Period of Support: Using Page EE (form page 5) 
of the Form PHS 398, follow the instructions in the Form PHS 398 application 
kit. See 4 above. Provide specific justifications for costs for each year 
requested appropriate to the stage of development (e.g., planning, priority-
setting and implementation). Costs for each year would include administrative 
costs and developmental costs as needed within the $250,000 direct cost cap. 

6. Budgets Pertaining to Consortium/Contractual Arrangements: Use this 
category if more than one MSI or Cancer Center is being linked in a 
collaboration.  In this case, one of the MSI/Cancer Center institutions would 
have to serve as the primary grantee and subcontract for the consortial 
involvement of the other MSI/Cancer Center.

7. Biographical Sketch of Principal Investigator: Use Page FF (form page 6) of 
the Form PHS 398 and follow the instructions in the application kit.

8. Biographical Sketch of the Co-Investigator: Use Page FF (form page 6) and 
follow the instructions in the Form PHS 398 application kit.

9. Biographical Sketch of Key Professional Personnel of the MSI or the Cancer 
Center.  Use Page FF (form page 6) as above.  This section should include all 
professional individuals who serve in middle leadership roles.  

10. List of participating faculty/members of the MSI or Cancer Center 
alphabetically by name.  Include for each individual their degree, department 
affiliation or equivalent, and research or other interest (e.g., research 
area, training, or education).

11. Other Support: Using Page GG (format page 7), provide other support only 
for the Principal Investigator, Co-Investigator and other key professional 
personnel at either the MSI or the Cancer Center and follow the instructions 
in the Form PHS 398 application kit.

12. Resources:  Using Page HH (form page 8, follow the instructions in the 
Form PHS 398 application kit.

13. COLLABORATIVE PLAN:  

Special Introductory Statement for Revised Application (if applicable): 

This section should include a summary of not more than three pages of the 
additions, deletions, and changes in the revised application, placing 
particular emphasis on responses to the criticisms and issues raised in the 
Summary Statement.  The changes in the full text must be clearly marked by 
appropriate bracketing, indenting, or changes in type setting, unless the 
changes are so extensive as to include most of the text.

A. Background:  

This section should be the same for MSI and Cancer Center P20 MI/CCP 
applications.  It should describe the characteristics of the MSI and the 
Cancer Center that will contribute to the planning effort.  It should clearly 
denote the nature of the interactions and deliberations that occurred and the 
individuals involved between the MSI and the Cancer Center during the 
preparation of these applications.

When Cancer Centers are NOT NCI-designated Cancer Centers, there should be a 
clear summary of the qualities of the institution that demonstrate that it has 
a highly organized and integrated cancer research program comparable to an 
NCI-designated Cancer Center.

B. Letter of Support:

This letter of support would be required under the following situations:

   1. If the Principal Investigators of the MSI or Cancer Center are less 
experienced individuals, this letter of support should be from a senior member 
of the MSI or Cancer Center (e.g., Department Chair, Dean, Cancer Center 
Director) and should include a statement describing how Principal Investigator 
will be provided with appropriate mentoring and the necessary support to 
ensure the success of this collaborative planning effort.  This support could 
be in the form of protected time for junior faculty to participate in and 
focus on the objectives of this grant and discretionary resources that will be 
made available to the Principal and Co-Principal Investigators.

   2. If the nature of the potential application will require significant 
institutional commitments to ensure its success, such a training program or an 
education program must have the commitment both from institutional leaders of 
the MSI (e.g., Dean, President) and the Cancer Center (e.g., Cancer Center 
Director).

C. Chronological Estimates of Planning, Priority-setting and Implementation 
Stages: (No more than 5 pages):

This section should be the same for the MSI and the Cancer Center application.  
Each application should include a chronological table listing the specific 
first year, second year, and third year (as applicable) objectives that are 
expected to be achieved.  Clearly, applicants who have had minimal 
interactions and progress in planning should apply for three years of support 
incorporating all three stages while those who have had significant 
opportunity to plan should apply for two years of support.  For each 
objective, a brief statement should be made about the separate contributions 
of the MSI and the Cancer Center in order to achieve success.  The final 
objective of the P20 must be the submission of a specific grant application 
(R03, R01, T32, K12, R25T, R25E project on Program Project Research Grant 
(P01) or Spore Grant (P50) to the NCI or other funding agencies. 
.
D. Initial Planning Stage: 

For three-year applicants, clearly describe the kinds of planning activities 
that the MSI and the Cancer Center will conduct to ensure a highly interactive 
and integrated effort between their faculty and scientists.  Relate each 
planning activity (e.g., workshop, retreat, executive meeting) to specific 
objectives above and name the specific faculty and interests (e.g., training, 
clinical oncology researchers, research in prostate cancer, establishing new 
curriculum in nutrition, etc.) who will participate in each activity. 

For two-year applicants, this section should document the prior experience, 
interaction and progress in planning.

E. Priority–setting Stage: 

Clearly describe how the specific projects/programs will be prioritized and 
selected for implementation based on their merit and greatest potential for 
success.

F. Implementation Stage: 

Three-year applicants should provide some general outline including as much 
information as possible about how they envision the implementation stage but 
are not expected to provide specific details.  

Two-year applicants should clearly describe the specific pilot 
projects/programs to be supported.  Pilots must have co-leadership by 
individuals from the MSI and the Cancer Center.  Each pilot project/program 
should include the following specific information:

(1). Title
(2). Names of the Co-Leaders from the MSI and the Cancer Center
(3). One paragraph abstract
(4). One paragraph describing how this pilot project will relate to the 
overall objectives of the collaboration as described in the Background section 
above.
(5). Detailed budget page for initial budget period using page DD from form 
PHS 398.
(6). Biographical Sketches of Co-Leaders
(7). Pilot Research Proposal (up to five pages)
(8). A description of what aspects of the research proposal will be conducted 
at the MSI and/or the Cancer Center 
(9). Human Subjects**

**NOTE:  (1) All NIH-supported biomedical or behavioral research projects 
involving human subjects must consider appropriate inclusion of Gender and 
Minorities and Children as noted on pages 16 and 17 and 27-33 of the Form PHS 
398 instructions; (2) Research dealing with Human Subjects and Vertebrate 
Animals must be accompanied by appropriate documentation as described on pages 
17 and 18 of the Form PHS 398 instructions; (3) Research components involving 
clinical trials must include provisions for rigorous data management, quality 
assurance, and auditing procedures.  Funds should be budgeted for these 
activities and should be justified.  The proposed provisions should not 
duplicate review and monitoring systems already in place at the institution.  
For any cancer treatment protocol supported directly or indirectly by the P20 
MI/CCP, informed consent forms, early stopping rules and procedures to detect 
and monitor adverse drug reactions (ADR) must be provided in the application, 
or in the case of protocols subsequent to funding of a P20 MI/CCP, to the NCI 
program director.
 
G. Human Subjects:  

Follow the directions and instructions provided in the Form PHS 398 
application kit.

H. Vertebrate Animals:

Follow the directions and instructions provided in the Form PHS 398 
application kit.

I. Literature Cited

Follow the directions and instructions provided in the Form PHS 398 
application kit.

J. Consortial/Contractual Arrangements

Follow the directions and instructions provided in the Form PHS 398 
application kit.

14. Appendix Material

Follow the directions and instructions provided in the Form PHS 398 
application kit.

15. Checklist

Follow the directions and instructions provided in the Form PHS 398 
application kit.

REVIEW CONSIDERATIONS  

Upon receipt, applications will be reviewed for completeness by the Center for 
Scientific Review (CSR) and responsiveness to ELIGIBILITY REQUIREMENTS and 
responsiveness to the SPECIAL REQUIREMENTS AND PROVISIONS OF PLANNING GRANTS 
FOR MINORITY INSTITUTION/CANCER CENTER COLLABORATIONS by the NCI. Incomplete 
and/or non-responsive applications will be returned to the applicant without 
further consideration.

Applications that are complete and responsive to the RFA will be evaluated by 
an appropriate peer review group convened by the Division of Extramural 
Activities of the NCI.  The initial review group will first evaluate the 
applications for meeting the criteria in the General Features below.  Those 
applications that meet the criteria in the General Features (intent of the 
RFA) will be further evaluated for scientific and technical merit in 
accordance with the other review criteria stated below. As part of the initial 
merit review, all applications will receive a written critique and undergo a 
process by which only those applications deemed to have the highest scientific 
merit, generally the top half of the applications under review, will be 
discussed, assigned a priority score, and receive a second level review by the 
National Cancer Advisory Board (NCAB).
 
The application from the MSI and the application from the Cancer Center will 
be reviewed together as ONE collaboration.  
 
Review Criteria:

This initiative is quite broad in scope and includes cancer research, cancer 
training and career development and cancer education objectives.  Under these 
circumstances, the review criteria are not organized under the traditional 
headings of Significance, Approach, Environment, Investigator and Innovation 
typically used for NIH research grants.  Reviewers will have to use 
considerable flexibility in determining the merit of a broad range of 
possibilities that can expand research, training and career development 
opportunities for minority scientists and students.

Applicants can either apply for two or three years of support depending on 
their previous experience, interactions and planning history, consequently 
reviewers must evaluate the following:

1. Strength of the evidence that the researchers and faculty of the MSI and 
the Cancer Center worked closely together in the preparation of the 
application.
 
2. As applicable, the degree to which the letters of support from senior 
faculty and/or institutional/center leaders address the need for mentoring of 
inexperienced Principal Investigators or for specific institutional/center 
commitments to ensure the success of the collaboration.

3. As applicable, the adequacy of provisions made for day-to-day oversight, 
coordination, support and logistical services needed to make the collaboration 
successful.

4. Initial Planning Stage:

For three-year applicants: 

   a. The adequacy of the different planning methods proposed by the MSI and 
Cancer Center to fully explore areas of opportunity and to ensure highly 
interactive and integrated efforts between individual scientists (e.g., 
research project) and/or between faculty and scientists (e.g., training 
program, education program).

   b. The adequacy and duration of the initial planning stage needed to 
identify areas of potential collaboration. 

For two-year applicants: 

   a. The quality and merit of the documented planning process used for 
identifying areas ready for prioritization and/or for pilot testing. 

   b. The appropriateness and adequacy of the specific faculty and scientists 
identified from the MSI and the Cancer Center to contribute effectively to 
each aspect of this planning effort. 

5. Priority-setting Stage:

   a. The adequacy of the experience and qualifications of the individuals who 
will take part in prioritizing and selecting specific pilot projects/programs 
for implementation.  

   b. The adequacy of the process used for selecting pilot projects/programs 
for implementation based on their merit and their potential for successful 
acquisition of preliminary data during the period of requested grant support.

6. Pilot Projects/Programs

For three-year applicants: 

   a. The potential of the Co-Investigators and the collaborative plan to 
prioritize and implement specific pilot projects/programs.  

   b. The likelihood that potential pilot projects/programs will emerge from 
this collaboration that will be successful as specific grant applications.

For two-year applicants: 

   a. The qualifications of the Co-leaders to implement the pilot 
project/program.  

   b. The merit of the project/program and its feasibility to acquire the 
necessary preliminary data to become competitive for specific grant support 
(e.g., R03, R01, P01, P50, K12, T32, R25). 

7. Other Considerations:

The initial review group will also examine the appropriateness of the proposed 
budgets and duration; the adequacy of plans to include both genders and 
minorities and their subgroups as appropriate for scientific goals of the 
research and plans for recruitment and retention of subjects; the adequacy of 
plans for including children as appropriate for the scientific goals of the 
research, or the justification for exclusion; the provisions for the 
protection of human and animal subjects; and the safety of the research 
environment.
 
Overall Evaluation and Scoring of Application:
 
The overall degree of merit for the collaboration, as reflected by one 
priority score will be assigned to the MSI and the Cancer Center applications.  

For three-year applications, the score will be based primarily on the 
potential to develop projects/programs that will compete successfully for 
specific grant support.  

For two-year applications, the score should be based on the merit of the 
specific programs proposed and their likelihood to compete successfully for 
grant support with appropriate preliminary data.

AWARD CRITERIA
 
Each set of two applications from an MSI and a Cancer Center will compete for 
funds with all other collaborations in response to this RFA. Applications 
recommended by the NCAB will be considered for award based upon (a) scientific 
and technical merit as determined by peer reviewers; (b) the program 
priorities of the NCI, and (c) availability of funds.

INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS 

It is the policy of the NIH that women and members of minority groups and 
their sub- populations must be included in all NIH-supported biomedical and 
behavioral research projects involving human subjects, unless a clear and 
compelling rationale and justification is provided indicating that inclusion 
is inappropriate with respect to the health of the subjects or the purpose of 
the research.  This policy results from the NIH Revitalization Act of 1993 
(Section 492B of Public Law 103-43). 

All investigators proposing research involving human subjects should read the 
UPDATED "NIH Guidelines for Inclusion of Women and Minorities as Subjects in 
Clinical Research," published in the NIH Guide for Grants and Contracts on 
August 2, 2000 
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html); 
a complete copy of the updated Guidelines is available at 
http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm: The 
revisions relate to NIH defined Phase III clinical trials and require: a) all 
applications or proposals and/or protocols to provide a description of plans 
to conduct analyses, as appropriate, to address differences by sex/gender 
and/or racial/ethnic groups, including subgroups if applicable; and b) all 
investigators to report accrual, and to conduct and report analyses, as 
appropriate, by sex/gender and/or racial/ethnic group differences.

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS.  

It is the policy of NIH that children (i.e., individuals under the age of 21) 
must be included in all human subjects research, conducted and supported by 
the NIH, unless there are clear and compelling scientific and ethical reasons 
not to include them. This policy applies to all initial (Type I) applications 
submitted for receipt dates after October 1, 1998. 
 
All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines on the Inclusion of Children as participants in 
Research Involving Human Subjects "that was published in the NIH Guide for 
Grants and Contracts, March 6, 1998, and is available at the following URL 
address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html.

REQUIRED EDUCATION IN THE PROTECTION OF HUMAN RESEARCH PARTICIPANTS

All investigators proposing research involving human subjects should read the 
policy that was published in the NIH Guide for Grants and Contracts, June 5, 
2000 (Revised August 25, 2000), available at the following URL address 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

URLS IN NIH GRANT APPLICATIONS OR APPENDICES

All applications and proposals for NIH funding must be self-contained within 
specified page limitations.  Unless otherwise specified in an NIH 
solicitation, internet addresses (URLs) should not be used to provide 
information necessary to the review because reviewers are under no obligation 
to view the Internet sites.  Reviewers are cautioned that their anonymity may 
be compromised when they directly access an Internet site.

HEALTHY PEOPLE 2010

The Public Health Service (PHS) is committed to achieving the health promotion 
and disease prevention objectives of "Healthy People 2010," a PHS-led national 
activity for setting priority areas. This RFA, Planning Grant For Minority 
Institution/Cancer Center Collaborations, is related to the priority area of 
cancer.  Potential applicants may obtain a copy of "Healthy People 2010" at 
http://www.health.gov/healthypeople/.

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance No. 
93.398, Cancer Research Manpower.  Awards are made under authorization of 
Sections 301 and 405 of the Public Health Service Act as amended, (42 USC 241 
and 284) and administered under NIH grants policies and Federal Regulations 42 
CFR Parts 52 and 45 CFR Parts 74 and  92. This program is not subject to the 
intergovernmental review requirements of Executive Order 12372 or Health 
Systems Agency review. 
 
The PHS strongly encourages all grant and contract recipients to provide a 
smoke-free workplace and promote the non-use of all tobacco products.  In 
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking 
in certain facilities (or in some cases, any portion of a facility) in which 
regular or routine education, library, day care, health care or early 
childhood development services are provided to children.  This is consistent 
with the PHS mission to protect and advance the physical and mental health of 
the American people.


Return to Volume Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.